0920-0978 2024 Laboratory Testing Practices For Candidemia Questio

[NCEZID] Emerging Infections Program

Att19_HAIC_2024 Laboratory Survey Candidemia

OMB: 0920-0978

Document [pdf]
Download: pdf | pdf
Lab ID No. [][][][][][]
2024 LABORATORY TESTING PRACTICES FOR CANDIDEMIA QUESTIONNAIRE
1) What kind of laboratory is this? (select one)
Hospital laboratory
Commercial laboratory (Quest, etc.)

Other (specify) ______________________
Unknown

2) Does this laboratory ever receive blood cultures from nursing homes or other long term care facilities?
Yes
No
Unknown
3) Does the clinical microbiology laboratory at your institution have a separate mycology section or laboratory?
Yes
No
Unknown
4) What kind of blood culture system does your laboratory use? (check all that apply)
BacT/Alert
Bactec FX
BacT/Alert 3D
Isolator tubes
VersaTREK
Other (specify) ______________________
Bactec 9240
5) What is the approximate volume of fungal cultures ordered and performed annually in your laboratory for
any specimen type?
Specify number: ______________
Unknown
6) What is the approximate volume of fungal blood cultures ordered and performed annually in your laboratory?
Specify number: ______________ Unknown
YEAST IDENTIFICATION
7) Does this laboratory offer yeast identification (either onsite or sent to another laboratory)?
Yes
No (-------- If No, SKIP TO QUESTION 18 --------)
Unknown (is there another laboratory staff member who can assist with the questionnaire?)
8) Where is yeast identification done? (check the most applicable)
On-site, in the laboratory
Sent to commercial lab
Sent to affiliated hospital lab
Sent to other local/regional, non-affiliated reference or public health laboratory
Other ______________________________
Unknown

Answer the following questions for the lab selected in question 8.
9) How does this lab identify yeast? (check all that apply)
MALDI-TOF Bruker (Biotyper)
MALDI-TOF bioMerieux (VITEK MS)
VITEK 2
API 20C
DNA sequencing
PNA-FISH
BactiCard Candida

BD Phoenix
MicroScan
RapID Plus
Other (specify) ______________________
Unknown

10) Does this laboratory routinely use chromogenic agar for the identification or differentiation of Candida
isolates?
Yes
No
Unknown
11) Species-level identification is performed for Candida spp. isolated from which of the following?
a. Blood isolates
Yes, always

2024

Yes, with clinician order

No

Unknown

Page 1 of 4

Lab ID No. [][][][][][]
b. Other normally sterile body site isolates
Yes, always
Yes, with clinician order
c. Abdominal isolates
Yes, always
Yes, with clinician order

No

Unknown

No

Unknown

d. Respiratory isolates
Yes, always

Yes, with clinician order

No

Unknown

e. Urine isolates
Yes, always

Yes, with clinician order

No

Unknown

Other (specify) ____________________
Yes, always
Yes, with clinician order

No

Unknown

f.

12) How does this laboratory meet proficiency testing requirements for yeast identification?
Commercial provider (specify) _________________
Internal alternate assessments (specify) __________________
13) Does this laboratory employ PCR molecular tests to identify Candida from blood specimens?
Yes (go to Q14)
No (go to Q17)
Unknown
14) Does this laboratory employ the T2Candida Panel to identify Candida from blood specimens?
Yes (go to Q14a)
No (go to Q15)
Unknown
a. If Yes, when did this lab first start using T2Candida Panel? Date (mm/dd/yyyy): ____/____/________
b. If Yes and you get a positive result on T2Candida Panel, does this lab culture the blood to obtain an
isolate?
Yes, always
No
Yes, with a clinical order
Unknown
15) Does this laboratory employ the BioFire (FilmArray) to identify Candida from blood culture?
Yes (go to Q15a)
No (go to Q16)
Unknown
a. If Yes, when did this lab first start using BioFire? Date (mm/dd/yyyy): ____/____/________
b. If Yes and you get a positive result on BioFire, does this lab culture the blood to obtain an isolate?
Yes, always
No
Yes, with a clinical order
Unknown
16) Does this laboratory employ any other PCR molecular tests to identify Candida from blood specimens?
Yes (specify) ______________________
No
Unknown
17) If No for Question 13, does this laboratory have plans to employ PCR molecular tests for Candida
identification in the near future (e.g., T2Candida Panel, BioFire)?
Yes (specify) ___________________
Unknown
No
Not applicable
ANTIFUNGAL SUSCEPTIBILITY TESTING
18) Does this laboratory offer any antifungal susceptibility testing for Candida (either onsite or sent to another
laboratory)?
Yes
No (-------- If No, QUESTIONNAIRE COMPLETE --------)
Unknown (is there another laboratory staff member who can assist with the questionnaire?)

2024

Page 2 of 4

Lab ID No. [][][][][][]
19) Where is antifungal susceptibility testing (AFST) done? (check the most applicable)
On-site, in the laboratory (go to Q20)
Sent to commercial lab (-------- If not an on-site laboratory, QUESTIONNAIRE COMPLETE --------)
Sent to affiliated hospital lab
Sent to other local/regional, non-affiliated reference or public health laboratory
Other ______________________________
Unknown

Answer the following questions for the lab selected in question 19.
20) Is antifungal susceptibility testing available for any of the following antifungal drugs (check all that apply):
Fluconazole
Caspofungin
Voriconazole
Amphotericin B
Itraconazole
Flucytosine
Posaconazole
Other (specify) __________________
Micafungin
Unknown
Anidulafungin
21) What methods are used for AFST, excluding Amphotericin B? (check all that apply)
Broth microdilution with laboratory
Vitek (bioMerieux)
developed plates
Other ______________________________
YeastOne (Thermo Scientific™ Sensititre™)
Unknown
Gradient diffusion (E test)
22) What methods are used for AFST of Amphotericin B? (check all that apply)
Broth microdilution with
Vitek (bioMerieux)
laboratory developed plates
Other ______________________________
YeastOne (Thermo Scientific™ Sensititre™)
Unknown
Gradient diffusion (E test)
23) How does this laboratory meet proficiency testing requirements for antifungal susceptibility testing, if
performed?
Commercial provider (specify) _________________
Internal alternate assessments (specify) __________________
24) How are results of AFST reported when breakpoints are available? (select one)
Categorical interpretation only (susceptible,
Both--categorical interpretation PLUS MIC
resistant, etc.)
Unknown
MIC only
25) How are results of AFST reported when breakpoints aren’t available? (select one)
MIC only
Epidemiological cutoff values (ECVs)
Unknown
26) For what type of Candida isolates is antifungal susceptibility testing (AFST) performed automatically? (check
all that apply)
Blood isolates
No AFST performed automatically (requires
Other normally sterile body site isolates
order from a clinician)
Other (specify) ______________________
Unknown

2024

Page 3 of 4

Lab ID No. [][][][][][]
27) When is AFST performed for the following Candida spp.?
a. C. albicans
Performed automatically (Go to 27ai)
Performed with a clinician’s order (Go to 27ai)
Not performed
i.

Drugs for which AFST is performed on C. albicans (check all that apply):
Micafungin
Fluconazole
Other
Anidulafungin
Voriconazole
Unknown
Caspofungin
Amphotericin B

b. C. glabrata
Performed automatically (Go to 27bi)
Performed with a clinician’s order (Go to 27bi)
Not performed
i.

Drugs for which AFST is performed on C. glabrata (check all that apply):
Micafungin
Fluconazole
Other
Anidulafungin
Voriconazole
Unknown
Caspofungin
Amphotericin B

c. C. parapsilosis
Performed automatically (Go to 27ci)
Performed with a clinician’s order (Go to 27ci)
Not performed
i.

Drugs for which AFST is performed on C. parapsilosis (check all that apply):
Micafungin
Fluconazole
Other
Anidulafungin
Voriconazole
Unknown
Caspofungin
Amphotericin B

d. Other Candida spp.
Performed automatically (Go to 27di)
Performed with a clinician’s order (Go to 27di)
Not performed
i.

Drugs for which AFST is performed on other Candida spp. (check all that apply):
Micafungin
Fluconazole
Other
Anidulafungin
Voriconazole
Unknown
Caspofungin
Amphotericin B

28) Is this laboratory tracking susceptibility trends for Candida spp. isolates tested in your lab?
Yes

No

Unknown

------------------------------------------------ END OF QUESTIONNAIRE ------------------------------------------------

2024

Page 4 of 4


File Typeapplication/pdf
AuthorAngela Ahlquist
File Modified2023-08-10
File Created2023-08-10

© 2024 OMB.report | Privacy Policy